Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR3046)
Name
Raltitrexed
Synonyms
Raltitrexed; Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ICI D1694; UNII-FCB9EGG971; D1694; CHEBI:5847; C21H22N4O6S; Raltitrexed (Tomudex); ZD-16; FCB9EGG971; ZD 1694; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_CID_26482; DSSTox_RID_81653; DSSTox_GSID_46482; (S)-2-(5-(Methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)-methyl)amino)thiophene-2-carboxamido)pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid; (2S)-2-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)formamido]pentanedioic acid; (S)-2-(5-(methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid; D16; Tomudex (TN); D 1694; CAS-112887-68-0; Raltitrexed (JAN/USAN/INN); (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 1hvy; 2kce; 2tsr; ZN-D1694; KS-5069; ZD1694; Raltitrexed; SCHEMBL7438; MLS001424225; MLS006010125; N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid; Raltitrexed [USAN:INN:BAN]; GTPL7403; DTXSID0046482; BDBM18795; QCR-125; 1i00; HMS2052I03; HMS3715P08; AMY42113; ZINC3832372; Tox21_112237; BDBM50027655; MFCD00864168; NSC639186; s1192; AKOS015894877; AKOS015994729; Tox21_112237_1; CCG-101075; CCG-221273; DB00293; NC00325; NCGC00263534-02; HY-10821; L-Glutamic acid, N-((5-(((1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-; L-Glutamic acid, N-[[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-; NCI60_013008; SMR000469217; SMR002529608; BCP0726000267; SW197705-2; C11372; D01064; S-7682; AB00698356-05; 134189-EP2275102A1; 134189-EP2292233A2; 887R680; SR-01000763351; J-524216; SR-01000763351-3; BRD-K89839824-001-01-2; Q15304877; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; N-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}thiophen-2-yl)carbonyl]-L-glutamic acid; N-[[5-[[(1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic acid
    Click to Show/Hide
Molecular Type
Small molecule
Disease Rectum cancer [ICD-11: 2B92] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H22N4O6S
PubChem CID
135400182
Canonical SMILES
CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1
InChI
1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
InChIKey
IVTVGDXNLFLDRM-HNNXBMFYSA-N
CAS Number
CAS 112887-68-0
ChEBI ID
CHEBI:5847
TTD Drug ID
D01KKQ
DrugBank ID
DB00293
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Fluoroorotic acid      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model LoVo CVCL_0399 Colon adenocarcinoma Homo sapiens
HT-29 CVCL_0320 Colon adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Target and Pathway
Target(s) Candida thymidylate synthase (Candi TMP1)  Molecule Info  [3]
BioCyc Pyrimidine deoxyribonucleotides biosynthesis from CTP Click to Show/Hide
2 Pyrimidine deoxyribonucleotides de novo biosynthesis
3 Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis
4 Superpathway of pyrimidine deoxyribonucleoside salvage
5 DTMP de novo biosynthesis (mitochondrial)
6 Pyrimidine deoxyribonucleosides salvage
KEGG Pathway Pyrimidine metabolism Click to Show/Hide
2 One carbon pool by folate
3 Metabolic pathways
Panther Pathway De novo pyrimidine deoxyribonucleotide biosynthesis Click to Show/Hide
2 Formyltetrahydroformate biosynthesis
Pathwhiz Pathway Pyrimidine Metabolism Click to Show/Hide
Pathway Interaction Database E2F transcription factor network Click to Show/Hide
Reactome E2F mediated regulation of DNA replication Click to Show/Hide
2 Pyrimidine biosynthesis
3 G1/S-Specific Transcription
WikiPathways Trans-sulfuration and one carbon metabolism Click to Show/Hide
2 Retinoblastoma (RB) in Cancer
3 One Carbon Metabolism
4 Integrated Pancreatic Cancer Pathway
5 miR-targeted genes in muscle cell - TarBase
6 miR-targeted genes in lymphocytes - TarBase
7 miR-targeted genes in leukocytes - TarBase
8 miR-targeted genes in epithelium - TarBase
9 Metabolism of nucleotides
10 Fluoropyrimidine Activity
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7403).
Reference 2 Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs. 2007 Aug;18(7):793-800.
Reference 3 DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China